Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
138.70
+2.07 (1.52%)
Oct 13, 2025, 11:01 AM EDT - Market open
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $687.50M in the quarter ending June 30, 2025, with 16.49% growth. This brings the company's revenue in the last twelve months to $2.51B, up 18.42% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.51B
Revenue Growth
+18.42%
P/S Ratio
5.44
Revenue / Employee
$1,394,389
Employees
1,800
Market Cap
13.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NBIX News
- 5 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - PRNewsWire
- 6 days ago - Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise - PRNewsWire
- 7 days ago - Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PRNewsWire
- 20 days ago - Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden - PRNewsWire
- 21 days ago - Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder - PRNewsWire
- 25 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript - Seeking Alpha
- 26 days ago - Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha